# Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Source: https://onco.cc/trials/nct06107868/  
OnCo record `nct06107868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Lunresertib run by University Health Network, Toronto, active and no longer recruiting.

## Summary

Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer is a phase 1 interventional study registered as NCT06107868 by University Health Network, Toronto, with 6 participants planned, started 2024-03-20. Conditions recorded: Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer and Advanced Cancer. Interventions recorded: RP-6306, Carboplatin and Paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06107868
- Phase: 1
- Setting: Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer
- Sponsor: University Health Network, Toronto
- Enrolled: 6

## Sources

- ClinicalTrials.gov NCT06107868: https://clinicaltrials.gov/study/NCT06107868

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Lunresertib](https://onco.cc/drugs/lunresertib/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/), [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06107868.json